Publication Date
10-1-2021
Journal
Nature Medicine
Abstract
Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg
Keywords
Adult, Antiretroviral Therapy, Highly Active, Antiviral Agents, Broadly Neutralizing Antibodies, CD4-Positive T-Lymphocytes, Double-Blind Method, Female, HIV Envelope Protein gp120, HIV Infections, HIV-1, Humans, Male, Middle Aged, Peptide Fragments, Placebos, Viral Load, Young Adult